scholarly article | Q13442814 |
P50 | author | Mark A Fiala | Q60370573 |
P2093 | author name string | Shireen Vali | |
Taher Abbasi | |||
Abdel Kareem Azab | |||
Feda Azab | |||
Ravi Vij | |||
Barbara Muz | |||
Pilar de la Puente | |||
Joseph Abraham | |||
Anuj Tyagi | |||
Zeba Sultana | |||
Nicholas Potter | |||
Jacob Paasch | |||
P2860 | cites work | PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? | Q24296651 |
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation | Q27684731 | ||
High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation | Q28236353 | ||
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway | Q29616144 | ||
Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement | Q30160287 | ||
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. | Q30487339 | ||
RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. | Q30488936 | ||
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib | Q34013386 | ||
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma | Q34124937 | ||
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. | Q34184917 | ||
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib | Q34291281 | ||
Multiple myeloma. | Q34362643 | ||
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone | Q34420112 | ||
The molecular classification of multiple myeloma | Q34530992 | ||
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma | Q34815786 | ||
Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells. | Q35564293 | ||
Targeting the PI3K-Akt pathway in human cancer: rationale and promise | Q35571372 | ||
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment | Q35776423 | ||
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. | Q36155317 | ||
Bone marrow microenvironment and the identification of new targets for myeloma therapy | Q36162703 | ||
Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo | Q36697045 | ||
Emerging drugs in multiple myeloma | Q36758600 | ||
The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells | Q36815262 | ||
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. | Q36986301 | ||
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors | Q37187543 | ||
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. | Q37250634 | ||
Latest advances and current challenges in the treatment of multiple myeloma | Q37986287 | ||
Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives | Q38021160 | ||
Carfilzomib | Q38080038 | ||
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Q38406496 | ||
The AKT kinase is activated in multiple myeloma tumor cells | Q38459102 | ||
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations | Q39338784 | ||
Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition | Q39502963 | ||
Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice | Q39564473 | ||
Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. | Q39585342 | ||
Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival | Q39621100 | ||
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. | Q39718152 | ||
Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line | Q39811914 | ||
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. | Q39827794 | ||
Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting. | Q39833233 | ||
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. | Q39986126 | ||
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells | Q40328451 | ||
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma | Q43761443 | ||
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications | Q44098361 | ||
Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms | Q44452179 | ||
Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway | Q44588841 | ||
Oncogenic signaling of class I PI3K isoforms | Q46902768 | ||
Multiple Myeloma | Q56453538 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | multiple myeloma | Q467635 |
P304 | page(s) | 89-101 | |
P577 | publication date | 2014-01-09 | |
P1433 | published in | British Journal of Haematology | Q4970200 |
P1476 | title | PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance | |
P478 | volume | 165 |
Q37032148 | A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma |
Q58729853 | Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib |
Q36086488 | Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast |
Q37697253 | Kinase inhibitors as potential agents in the treatment of multiple myeloma |
Q35594600 | Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines |
Q42608339 | MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma |
Q38211866 | Molecularly targeted therapies in multiple myeloma |
Q52859066 | Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance. |
Q38829287 | Nuclear-Targeting MSNs-Based Drug Delivery System: Global Gene Expression Analysis on the MDR-Overcoming Mechanisms |
Q53055574 | PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform. |
Q38914605 | Personalization of cancer treatment using predictive simulation |
Q55091606 | Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma. |
Q36843582 | Suppression of Nkx3.2 by phosphatidylinositol-3-kinase signaling regulates cartilage development by modulating chondrocyte hypertrophy |